(Q34069806)

30 July 2017

1 reference

title

Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options (English)

1 reference

30 July 2017

anti-retroviral agent

0 references

author name string

Kaufmann GR

series ordinal

1

1 reference

PubMed ID

11050451

30 July 2017

Cooper DA

series ordinal

2

1 reference

PubMed ID

11050451

30 July 2017

language of work or name

1 reference

1 October 2000

1 reference

Current Opinion in Microbiology

30 July 2017

1 reference

30 July 2017

3

1 reference

30 July 2017

5

1 reference

30 July 2017

508-514

1 reference

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

1 reference

7 January 2021

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900131-4

7 January 2021

10.1016/S1369-5274(00)00131-4

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11050451